Peg-filgrastim is a form of G-CSF with a sustained duration of action due to self-limited clearance. We administered 6 mg peg-filgrastim to 18 autograft recipients on day +1 after transplantation for ...

为解决自体造血干细胞移植(autoSCT)后中性粒细胞恢复延迟问题，研究人员开展了一项关于filgrastim(G-CSF)应用的回顾性研究。结果显示，使用filgrastim可使中性粒细胞恢复时间从14天缩短至11天(p0.001)，住院时间从15天缩短至13天(p=0.017)，且不增加血小板恢复延迟、中性 ...

Filgrastim alone and sequential sargramostim and filgrastim have been shown to be more effective than sargramostim alone in the mobilization of CD34 + cells after myelosuppressive chemotherapy (MC).

PURPOSE: The purpose of this study was to compare the effects of filgrastim, sargramostim, or sequential sargramostim and filgrastim on CD34 + cell yields and morbidity after myelosuppressive ...

New York, Dec. 27, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Filgrastim Market By Drug Type, By Indication, By ...

Association of Community-Level Social Vulnerability With Clinical Trial Discussion and Participation Among Cancer Survivors This was an observational, noninferiority, cohort study of patients from ...

A study published in the Journal of Managed Care & Specialty Pharmacy found that filgrastim and filgrastim-sndz were noninferior for the prevention of febrile neutropenia events that would require ...

Dublin, Jan. 14, 2021 (GLOBE NEWSWIRE) -- The "Filgrastim Biosimilars Global Market Opportunities and Strategies to 2030: COVID-19 Implications and Growth" report has been added to ...

Review the side-effects of Filgrastim as documented in medical literature. The term "side effects" refers to unintended effects that can occur as a result of taking the medication. In majority of the ...

GRANIX (tbo-filgrastim) Injection Teva announced that the FDA has approved Tbo-filgrastim (XM02 filgrastim injection solution), the first granulocyte colony-stimulating factor (G-CSF) to be approved ...

- APHEXDA is the first innovation in stem cell mobilization for multiple myeloma to be approved in the U.S. in a decade - - One dosage of APHEXDA plus filgrastim enabled a majority of patients to ...

New York, Feb. 08, 2023 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Filgrastim Biosimilars Global Market Report 2023" - https://www ...